To the Editor In their recent Original Investigation, Kas et al1 compared 5 different definitions of hyperprogressive disease (HPD) based on tumor growth rate (TGR) or tumor growth kinetics during immunotherapy for non–small cell lung cancer (NSCLC), using exclusively changes in target lesions measured in a prebaseline tumor assessment and 2 different time points: baseline and first tumor evaluation. For that purpose, they analyzed patients with advanced NSCLC treated with immune checkpoint inhibitor (ICI) treatment. The authors’ conclusion suggests that an increase in the TGR in patients receiving ICI therapy should be defined as HPD, and they propose a new definition: an increase greater than 20% by Response Evaluation Criteria in Solid Tumors, version 1.1 criteria and ΔTGR of greater than 100. However, we would like to highlight some additional aspects that should not be neglected.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Matos I, Garralda E. Clarification of Definitions of Hyperprogressive Disease During Immunotherapy. JAMA Oncol. 2021;7(1):136–137. doi:10.1001/jamaoncol.2020.5582
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: